Bipolar Disorder Trial, Recruiting NCT06022913 Sponsor: Reykjavik University Condition: Bipolar Disorder
Back to Bipolar Disorder

Bipolar Disorder Trial, Recruiting

NCT06022913
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who score in the clinical range for depression on a standard self-report questionnaire called the PHQ-9
  • People who have been diagnosed with depression based on a structured diagnostic interview called the DIAMOND
  • People who have been diagnosed with Bipolar I or Bipolar II Disorder using the DIAMOND diagnostic interview
  • People who have a working knowledge of written and spoken Icelandic, sufficient to participate in therapy and complete study assessments without needing a translator

Who may not be able to join:

  • People who have a current or past learning disability, brain injury or condition affecting brain function, or a dependence on drugs or alcohol that could affect their ability to engage with therapy
  • People who are currently at significant risk of self-harm or suicide that the trial site determines cannot be safely managed at the Bipolar outpatient clinic at Landspitali
  • People who do not currently have the capacity to give informed consent to participate
  • People who are currently receiving another form of psychological or talking therapy for depression or bipolar disorder
  • People whose treating clinician and therapist consider another condition — such as Post-Traumatic Stress Disorder or psychosis — to be the more important focus of treatment at this time

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Brynja B Magnúsdóttir, PhD, Reykjavik University

Phone: 8688371

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Reykjavik University
Registry
ClinicalTrials.gov
Start date
22 November 2023
Est. completion
31 December 2025

Where this trial is recruiting

Iceland

Primary endpoints

Minimally clinically significant improvement in depression symptoms for a majority of participants (>60%); Therapy uptake rate; Therapy completion rate; Change in activity levels as measured by consumer connected health devices; Change in Sleep Duration measured by health device; No significant adverse reaction for participants

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov